In this article
FDA Approval of Neoadjuvant and Adjuvant Durvalumab for Resectable NSCLC
August 2024: The Food and Drug Administration has granted approval for the use of durvalumab (Imfinzi, AstraZeneca) in combination with platinum-containing chemotherapy as a neoadjuvant treatment, followed by single-agent durvalumab as an adjuvant treatment after surgery.
This treatment is specifically intended for adults with resectable non-small cell lung cancer (NSCLC) who have tumors that are at least 4 cm in size and/or have positive lymph nodes. It is important to note that this treatment is only recommended for patients who do not have known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
Safety and Efficacy
The effectiveness of the treatment was assessed in the AEGEAN clinical trial (NCT03800134), which was a study involving 802 patients with previously untreated and surgically removable squamous or non-squamous NSCLC (Stage IIA to select Stage IIIB [AJCC, 8th edition]). The experiment was conducted in many centers and followed a randomized, double-blind, placebo-controlled design.
Participants were randomly assigned in equal numbers to receive either durvalumab or a placebo, along with platinum-based chemotherapy, every 3 weeks for a maximum of 4 cycles as a neoadjuvant treatment. This was followed by either continuous treatment with durvalumab alone or placebo, every 4 weeks for a maximum of 12 cycles as an adjuvant treatment.
The primary measures of effectiveness were event-free survival (EFS) as assessed by an independent review board, and pathological complete response (pCR) as assessed by a central pathology review board. The median event-free survival (EFS) was not determined (95% CI: 31.9, not estimable [NE]) in the durvalumab group and was 25.9 months (95% CI: 18.9, NE) in the placebo group (hazard ratio 0.68 [95% CI: 0.53, 0.88]; p-value=0.0039).
The rate of pathological complete response (pCR) was 17% (95% confidence interval [CI]: 13, 21) in the durvalumab arm and 4.3% (95% CI: 2.5, 7) in the placebo arm. During the prespecified interim analyses, the statistical significance of overall survival (OS) was not officially assessed. However, a descriptive analysis showed no evident negative impact.
The predominant adverse effects (≥20%) included anemia, nausea, constipation, exhaustion, musculoskeletal pain, and rash. Among the patients who were administered neoadjuvant durvalumab, 1.7% experienced adverse responses that prevented them from undergoing surgery, whereas only 1% in the placebo group faced the same issue.
The recommended dosage of durvalumab for patients weighing 30 kg or more is 1,500 mg every 3 weeks for neoadjuvant treatment and every 4 weeks for adjuvant treatment. The recommended dosage of durvalumab for patients weighing less than 30 kg is 20 mg/kg. Prior to administering chemotherapy on the same day, it is recommended to administer Durvalumab.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.